Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione).

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Steroids

• Publication date

  1993-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0039-128X(93)90029-MPMID 8273115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors

  2004cited by this paper
• Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.

  1992cited by this paper
• Exemestane (FCE 24304), a new steroidal aromatase inhibitor.

  1992cited by this paper
• Novel Irreversible Aromatase Inhibitors

  1990cited by this paper
• 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor.

  1988cited by this paper
• A Simple Method for 6-Methylenation of 3-Oxo-Δ4-steroids

  1982cited by this paper
• The degradation of hyodeoxycholic acid by Pseudomon as spp. N.C.I.B. 10590.

  1979cited by this paper
• Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione.

  1974cited by this paper
• [The course of the transformation of steroid 3,5-dienamines with formaldehyde].

  1973cited by this paper
• Über den Verlauf der Umsetzung von Steroid-3,5-dienaminen mit Formaldehyd

  1973cited by this paper
• Modified steroid hormones--LI. Application of the Vilsmeier reaction to 11-beta-hydroxy steroids.

  1969cited by this paper
• 5. Modified steroid hormones. Part XXVI. Some 6-methylated aromatic types

  1962cited by this paper
• 810. Modified steroid hormones. Part V. 6-Methylandrostane derivatives

  1957cited by this paper

• Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors.

  2026cites this paper
• Strategies to inhibit steroid cytochrome P450 enzymes to benefit human health: development of steroid ligands for P450s 17A1, 19A1, and 8B1 to treat cancer and obesity.

  2025cites this paper
• Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates

  2022cites this paper
• Study on the synthesis of Exemestane

  2018cites this paper
• Anticancer activity of novel steroidal 6‐substituted 4‐en‐3‐one D‐seco dinitriles

  2018cites this paper
• Characterization and pharmacogenetics of hepatic phase I exemestane metabolism

  2017influential citation
• In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β‐dihydroexemestane

  2017cites this paper
• Role of the UGT2B17 deletion in exemestane pharmacogenetics

  2017cites this paper
• Quinone‐related hexacyclic by‐products in the production process of exemestane

  2017cites this paper
• Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives

  2017influential citation
• Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases

  2016cites this paper
• Microbial-catalysed derivatization of anti-cancer drug exemestane and cytotoxicity of resulting metabolites against human breast adenocarcinoma cell line (MCF-7) in vitro.

  2016cites this paper
• Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane.

  2015cites this paper
• Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.

  2015cites this paper
• 17-Hydroexemestane: A Potent Inhibitor of CYP19 (Aromatase) and Substrate of CYP3A

  2014cites this paper
• Pharmacogenomics–Pharmacoepigenomics of Breast Cancer Therapy: Clinical Implications

  2014cites this paper
• Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.

  2014cites this paper
• Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer

  2013cites this paper
• Microbial transformation of anti-cancer steroid exemestane and cytotoxicity of its metabolites against cancer cell lines

  2013cites this paper
• Oxidation of unsaturated steroid ketones with hydrogen peroxide catalyzed by Fe(bpmen)(OTf)2. New methodology to access biologically active steroids by chemo-, and stereoselective processes

  2012cites this paper
• Detection of new urinary exemestane metabolites by gas chromatography coupled to mass spectrometry.

  2011cites this paper
• In Vitro Cytochrome P450-Mediated Metabolism of Exemestane

  2011cites this paper
• Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics

  2010cites this paper
• In Vitro P 450-Mediated Metabolism of Exemestane

  2010influential citation
• Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

  2010cites this paper
• Pharmacogenetics of Aromatase Inhibitors: Present Understanding and Looking to the Future

  2010influential citation
• Substituted androstanes as aromatase inhibitors

  2010cites this paper
• Development of Estrogen Antagonists as Pharmaceutical Agents

  2010cites this paper
• History of aromatase: saga of an important biological mediator and therapeutic target.

  2009cites this paper
• Synthesis of 17-Dihydroexemestane as a Reference Compound in Doping Control

  2009cites this paper
• 1,2-Dehydrogenation of steroidal 6-methylen derivatives. Synthesis of exemestane

  2009cites this paper
• Synthesis of DL-standishinal and its related compounds for the studies on structure-activity relationship of inhibitory activity against aromatase.

  2007cites this paper
• Detection of Exemestane and its metabolites using GC-MS and LC-MS-MS: a comparative study for screening purposes.

  2006cites this paper
• [Derivatives of exemestane--synthesis and evaluation of aromatase inhibition].

  2006cites this paper
• Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.

  2003cites this paper
• Overview of the Pharmacology of the Aromatase Inactivator Exemestane

  2002cites this paper
• Exemestane, a new steroidal aromatase inhibitor of clinical relevance.

  2002cites this paper
• Exemestane: treatment of breast cancer with selective inactivation of aromatase.

  2002cites this paper
• Expert Opinion on Investigational Drugs

  2000cites this paper
• Steroids: reactions and partial synthesis.

  2000cites this paper
• Pharmacology and clinical experience with exemestane

  2000cites this paper
• Exemestane experience in breast cancer treatment.

  1997cites this paper
• 6-Alkylandrosta-4,6-diene-3,17-diones and their 1,4,6-triene analogs as aromatase inhibitors. Structure-activity relationships.

  1997cites this paper
• Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay

  1996cites this paper
• Inhibition of aromatase.

  1996cites this paper